Cargando…
Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective
Therapeutic drug monitoring (TDM) of conventional cytotoxic chemotherapies is strongly supported yet poorly implemented in daily practice in hospitals. Analytical methods for the quantification of cytotoxic drugs are instead widely presented in the scientific literature, while the use of these thera...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147065/ https://www.ncbi.nlm.nih.gov/pubmed/37111768 http://dx.doi.org/10.3390/pharmaceutics15041283 |
_version_ | 1785034727049134080 |
---|---|
author | Briki, Myriam André, Pascal Thoma, Yann Widmer, Nicolas Wagner, Anna D. Decosterd, Laurent A. Buclin, Thierry Guidi, Monia Carrara, Sandro |
author_facet | Briki, Myriam André, Pascal Thoma, Yann Widmer, Nicolas Wagner, Anna D. Decosterd, Laurent A. Buclin, Thierry Guidi, Monia Carrara, Sandro |
author_sort | Briki, Myriam |
collection | PubMed |
description | Therapeutic drug monitoring (TDM) of conventional cytotoxic chemotherapies is strongly supported yet poorly implemented in daily practice in hospitals. Analytical methods for the quantification of cytotoxic drugs are instead widely presented in the scientific literature, while the use of these therapeutics is expected to keep going for longer. There are two main issues hindering the implementation of TDM: turnaround time, which is incompatible with the dosage profiles of these drugs, and exposure surrogate marker, namely total area under the curve (AUC). Therefore, this perspective article aims to define the adjustment needed from current to efficient TDM practice for cytotoxics, namely point-of-care (POC) TDM. For real-time dose adjustment, which is required for chemotherapies, such POC TDM is only achievable with analytical methods that match the sensitivity and selectivity of current methods, such as chromatography, as well as model-informed precision dosing platforms to assist the oncologist with dose fine-tuning based on quantification results and targeted intervals. |
format | Online Article Text |
id | pubmed-10147065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101470652023-04-29 Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective Briki, Myriam André, Pascal Thoma, Yann Widmer, Nicolas Wagner, Anna D. Decosterd, Laurent A. Buclin, Thierry Guidi, Monia Carrara, Sandro Pharmaceutics Review Therapeutic drug monitoring (TDM) of conventional cytotoxic chemotherapies is strongly supported yet poorly implemented in daily practice in hospitals. Analytical methods for the quantification of cytotoxic drugs are instead widely presented in the scientific literature, while the use of these therapeutics is expected to keep going for longer. There are two main issues hindering the implementation of TDM: turnaround time, which is incompatible with the dosage profiles of these drugs, and exposure surrogate marker, namely total area under the curve (AUC). Therefore, this perspective article aims to define the adjustment needed from current to efficient TDM practice for cytotoxics, namely point-of-care (POC) TDM. For real-time dose adjustment, which is required for chemotherapies, such POC TDM is only achievable with analytical methods that match the sensitivity and selectivity of current methods, such as chromatography, as well as model-informed precision dosing platforms to assist the oncologist with dose fine-tuning based on quantification results and targeted intervals. MDPI 2023-04-19 /pmc/articles/PMC10147065/ /pubmed/37111768 http://dx.doi.org/10.3390/pharmaceutics15041283 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Briki, Myriam André, Pascal Thoma, Yann Widmer, Nicolas Wagner, Anna D. Decosterd, Laurent A. Buclin, Thierry Guidi, Monia Carrara, Sandro Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective |
title | Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective |
title_full | Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective |
title_fullStr | Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective |
title_full_unstemmed | Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective |
title_short | Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective |
title_sort | precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: a perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147065/ https://www.ncbi.nlm.nih.gov/pubmed/37111768 http://dx.doi.org/10.3390/pharmaceutics15041283 |
work_keys_str_mv | AT brikimyriam precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT andrepascal precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT thomayann precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT widmernicolas precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT wagnerannad precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT decosterdlaurenta precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT buclinthierry precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT guidimonia precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective AT carrarasandro precisiononcologybypointofcaretherapeuticdrugmonitoringanddosageadjustmentofconventionalcytotoxicchemotherapiesaperspective |